Pinnacle Digest

Tag: Entheon

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board

Posted on by Pinnacle Digest
Entheon

Dr. David Erritzoe to provide guidance on psychopharmacological research Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research, has been […]

Read More…

Entheon Biomedical Corp. Announces DTC Eligibility

Posted on by Pinnacle Digest

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. The DTC is the largest […]

Read More…

Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

Posted on by Pinnacle Digest
Entheon-DNA

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, today announced the sponsorship of a clinical research study with Heading Health LLC (“Heading Health”) as institution and Dr. Steve Levine, MD, as principal investigator to determine the electroneurophysiologic effects of […]

Read More…

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Posted on by Pinnacle Digest
DNA molecule - entheon

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to […]

Read More…

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

Posted on by Pinnacle Digest
board of directors conference room

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta. Dr. Greenshaw is a […]

Read More…

Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

Posted on by Pinnacle Digest
DNA molecule - entheon

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emergency physician and addiction specialist, Dr. Dinesh Bayana as a medical advisor, providing expertise on the development of the Company’s DMT clinical program as […]

Read More…

Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness

Posted on by Pinnacle Digest
Pine Point Mining signs agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC (“Maya”) to help drive brand awareness of the Company’s Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. (“HaluGen”). […]

Read More…

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Posted on by Pinnacle Digest
signed agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with 3W Wellness Inc. (“Third Wave”) to help drive brand awareness of the company’s Psychedelics Genetic Test kit, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences […]

Read More…

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership

Posted on by Pinnacle Digest
DNA molecule - entheon

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) (“Silo Wellness”), a functional and psilocybin mushroom company and psychedelic wellness retreats operator, have signed a referral agreement (the “Agreement”), to help drive brand awareness of the […]

Read More…

Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

Posted on by Pinnacle Digest
Pine Point Mining signs agreement

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company has entered into a definitive agreement dated June 15, 2021 (the “Agreement“) with Lobo Genetics Inc. (“Lobo“), and 13089363 Canada Inc. (“Subco“), a wholly-owned subsidiary of Entheon. Pursuant to the Agreement, Entheon and Lobo will […]

Read More…